EXEL Quote, Trading Chart, Exelixis Inc.
home / stock / exel / exel quote
$22.33 Last:
4.79% Change Percent:
$21.5 Open:
$22.33 Previous Close:
$22.35 High:
$21.08 Low:
1,995,437 Volume:
03/05/2021 04:55:29 pm Last Trade Date Time:
Quotes are delayed by 15 to 20 minutes.
Last Five Trading Days
| Stock Date | Open Price | Close Price | High | Low | Volume |
|---|---|---|---|---|---|
| 2021-03-05 | 21.5 | 22.33 | 22.35 | 21.08 | 1,995,437 |
| 2021-03-04 | 21.25 | 21.31 | 21.65 | 20.86 | 1,572,645 |
| 2021-03-03 | 22.1 | 21.33 | 22.14 | 21.31 | 1,113,604 |
| 2021-03-02 | 22.21 | 22.01 | 22.23 | 21.84 | 2,010,230 |
| 2021-03-01 | 21.86 | 22.3 | 22.465 | 21.64 | 1,491,409 |
| 2021-02-26 | 22 | 21.66 | 22.29 | 21.4422 | 1,764,473 |
| 2021-02-25 | 22.7 | 21.96 | 22.71 | 21.79 | 1,366,927 |
| 2021-02-24 | 22.36 | 22.66 | 22.84 | 22.2 | 1,441,792 |
| 2021-02-23 | 21.64 | 22.215 | 22.4 | 21.29 | 1,635,345 |
| 2021-02-22 | 21.98 | 22.01 | 22.41 | 21.78 | 1,445,861 |
| 2021-02-19 | 22.49 | 22.21 | 22.78 | 22.1411 | 1,212,946 |
| 2021-02-18 | 22.44 | 22.26 | 22.5 | 21.81 | 2,023,361 |
| 2021-02-17 | 22.02 | 22.86 | 22.98 | 21.77 | 2,877,044 |
| 2021-02-16 | 22.02 | 21.94 | 22.69 | 21.71 | 3,548,179 |
| 2021-02-15 | 21.79 | 21.91 | 21.97 | 21.26 | 3,557,146 |
| 2021-02-12 | 21.79 | 21.91 | 21.97 | 21.26 | 3,546,742 |
| 2021-02-11 | 22.78 | 22.07 | 23 | 21.5516 | 4,235,730 |
| 2021-02-10 | 23.24 | 23.03 | 23.53 | 22.8268 | 1,361,381 |
| 2021-02-09 | 23.98 | 22.95 | 23.99 | 22.89 | 2,085,522 |
| 2021-02-08 | 23.52 | 23.81 | 23.97 | 23.16 | 1,653,190 |
News, Short Squeeze, Breakout and More Instantly...
-
– CHMP recommendation follows U.S. FDA approval of CABOMETYX in combination with OPDIVO in January – Exelixis, Inc. (NASDAQ: EXEL) today announced that its partner Ipsen received a positive opinion from the Committee for Medicinal Products for Human Use...
-
Presentations to be webcast on www.exelixis.com Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer will participate in fireside chats at the following virtual investor conferences in ...
-
– U.S. FDA designation based on an interim analysis of the phase 3 COSMIC-311 pivotal trial, in which cabozantinib demonstrated significant improvement in progression-free survival – – Exelixis expects to submit supplementary New Drug App...